ReviewTheranostics2022
Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle.
Review in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 1 synthesis or guideline pooled it, 217 citations in OpenAlex.
- Nanomaterial-Based Precision Drug Delivery for Advanced Nephrology Therapy: A Systematic Review.International journal of nanomedicine · 2026Pooled it
- Magnetically responsive electrospun fibers as programmable bioactive scaffolds: From formulation design to magnetically triggered therapy and regeneration.Bioactive materials · 2027Review
- Nanozymes: bridging nanoscale characteristics and catalytic mechanisms for advanced biomedical applications.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Metal oxide nanoparticles for acne vulgaris: mechanisms, synthesis, formulation, and translational prospects.RSC advances · 2026Review
- Closing the gap in aging science: unlocking the potential of nanoparticles in senescence therapy.Biogerontology · 2026Review
- Functional Repurposing of Magnetic Nanoparticle-Assisted Hyperthermia for Immune Cell Labelling and Tracking.Small methods · 2026Article
- Nano-Metal Hydrogen Therapy Targeting Immune Cells Drives Synergistic Anti-Tumor Effects.Molecules (Basel, Switzerland) · 2026Review
- Recent Advances in Ferrite-Based Materials for Biomedical Applications: A Comprehensive Review.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Molecular MRI monitoring of cyclodextrin therapy in murine abdominal aortic aneurysms.Scientific reports · 2026Article
- Interappointment pain reduction with three intracanal medicaments: A randomized clinical trial.Journal of conservative dentistry and endodontics · 2026Article
- Renaissance of Traditional Mineral Drugs in Cancer: Advanced Delivery Strategies and Bioengineering Approaches.Pharmaceutics · 2026Review
- In Vitro Antitumor Effects of Melittin Attached to FeMolecules (Basel, Switzerland) · 2026Article
- Stimuli-Responsive Peptides for Targeted Anticancer Drug Delivery: Current Advances and Future Outlook.Pharmaceutics · 2026Review
- Nanotechnology integration in oncology for advanced nanoparticle based strategies in targeted cancer diagnosis and treatment.Discover nano · 2026Review
- Elucidating the Influence of Serum Concentration, Sex, and Particle Size on Iron Oxide Nanoparticle-Lipid Biocorona Formation.Nanomaterials (Basel, Switzerland) · 2026Article
- Transient blood-brain barrier opening by focused ultrasound enhances ferumoxytol accumulation in glioblastoma.Materials today. Bio · 2026Article
- Nanomaterials reshaping cancer radiotherapy: Radiosensitization mechanisms, delivery and theranostic platforms, multimodal synergy, and clinical translation strategies.Materials today. Bio · 2026Review
- USPIO enhanced MR imaging in CNS tumors (UMIC): a study protocol.Nanomedicine (London, England) · 2026Article
- Multifunctional Magnetic Droplet Robots for Urological Applications: From Drug Delivery to Stone Retrieval.Micromachines · 2026Article
- Fluorescence bioimaging of drug nanocarriers based on Förster resonance energy transfer, aggregation-induced emission and aggregation-caused quenching.Acta pharmaceutica Sinica. B · 2026Review
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Ferumoxytol is an intravenous iron oxide nanoparticle formulation that has been approved by the U.S. Food and Drug Administration (FDA) for treating anemia in patients with chronic kidney disease. In recent years, ferumoxytol has also been demonstrated to have potential for many additional biomedical applications due to its excellent inherent physical properties, such as superparamagnetism, biocatalytic activity, and immunomodulatory behavior. With good safety and clearance profiles, ferumoxytol has been extensively utilized in both preclinical and clinical studies. Here, we first introduce the medical needs and the value of current iron oxide nanoparticle formulations in the market. We then focus on ferumoxytol nanoparticles and their physicochemical, diagnostic, and therapeutic properties. We include examples describing their use in various biomedical applications, including magnetic resonance imaging (MRI), multimodality imaging, iron deficiency treatment, immunotherapy, microbial biofilm treatment and drug delivery. Finally, we provide a brief conclusion and offer our perspectives on the current limitations and emerging applications of ferumoxytol in biomedicine. Overall, this review provides a comprehensive summary of the developments of ferumoxytol as an agent with diagnostic, therapeutic, and theranostic functionalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.